1. High cardiovascular risk in patients with diabetes and the cardiometabolic syndrome: mandate for statin therapy.
- Author
-
Gonzalez GL, Manrique CM, and Sowers JR
- Subjects
- Cardiovascular Diseases blood, Cardiovascular Diseases etiology, Cholesterol, LDL blood, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 drug therapy, Diabetic Nephropathies complications, Diabetic Nephropathies drug therapy, Dyslipidemias blood, Dyslipidemias complications, Dyslipidemias etiology, Humans, Metabolic Syndrome blood, Metabolic Syndrome drug therapy, Practice Guidelines as Topic, Risk Assessment, Risk Factors, Stroke etiology, Stroke prevention & control, Treatment Outcome, Cardiovascular Diseases prevention & control, Diabetes Mellitus, Type 2 complications, Dyslipidemias drug therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Metabolic Syndrome complications
- Abstract
Diabetes mellitus confers a high risk of cardiovascular morbidity and mortality and requires aggressive management of all cardiovascular risk factors, including diabetic dyslipidemia. Although levels of low-density lipoprotein cholesterol are often normal or only slightly elevated in persons with diabetes, lipid-altering therapy with statins has been shown in large, randomized, controlled trials to decrease the risk of cardiovascular complications in this patient population. A target low-density lipoprotein cholesterol level of <70 mg/dL is now a therapeutic option in patients at very high risk for coronary heart disease, including patients with diabetes. Diabetes is also a leading cause of end-stage renal disease. In addition to their lipid-modifying effects, statins have been shown to slow the progression of diabetic nephropathy and potentially exert other renoprotective effects; these benefits, however, remain to be confirmed in clinical trials.
- Published
- 2006
- Full Text
- View/download PDF